Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

RBCC: Insurance Companies, Researchers Drive Growth in Personalized Medicine



  RBCC: Insurance Companies, Researchers Drive Growth in Personalized Medicine

Business Wire

NOKOMIS, Fla. -- July 11, 2013

As Rainbow Coral Corp. (OTCBB: RBCC) works to develop new ways to capture a
share of the fast-growing, $232 billion personalized medicine market,
molecular pathology tests are rapidly transitioning from the laboratory to the
clinic.

GEN magazine reported this month that clinical laboratories began billing for
more than 100 molecular pathology tests using new CPT codes on the first of
this year, replacing the previous stacked-code system. That means the valuable
testing will be available to more patients through their insurance providers,
opening up personalized medicine to a much wider audience.

“We’re beginning to see patient care billers recognize that these tests work
and provide value to the patient, the physician and the healthcare system,”
said RBCC CEO Patrick Brown. “That’s a big breakthrough: Insurance coverage
decisions and physician test usage are big drivers of clinical utility.”

RBCC is developing a comprehensive media and marketing strategy designed to
introduce new innovations and treatment options in a U.S. personalized
medicine market poised for major expansion. PricewaterhouseCoopers predicts
that the sector could grow to as much as $452 billion by 2015. One of the
fastest-growing fields in the market is companion diagnostics, which could
grow to as large as $42 billion by 2015, according to industry analysts
TriMarkPublications.com.

RBCC has formed a biotech subsidiary, Rainbow BioSciences, to market and
develop new medical and research technology innovations to compete alongside
companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc.
(NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).

For more information on RBCC’s other biotech initiatives, please
visit www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visit www.RainbowBioSciences.com. For investment information and
performance data on the Company, please
visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
info@rainbowcoral.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement